Halozyme Therapeutics Shares Drop Following Leerink Partners Downgrade
Halozyme Therapeutics (HALO) shares fell by more than 13% on Friday following a downgrade from Leerink Partners. The stock decline was triggered by analyst concerns regarding the company's third-quarter results, which were described as only marginally exceeding Wall Street expectations. Analyst David Risinger noted that while the Q3 performance provided slight upside compared to forecasts, it lacked the significant momentum investors might expect. This sentiment contributed to a sharp sell-off in the developer of Enhanze drug delivery technology.
Tickers: $HALO